Table II.
Subject ID | CDR3 freq. | TCRβV family | V segment (start of CDR3) | N1 | D segment | N2 | J segment | TCRβJ family | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
10027 | 94% | 6-5 | C | A | S | I | H | Q | G | S | T | E | A | F | F | 1-1 | ||||||||
tgt | gcc | agc | atc | cat | caa | ggg | agc | act | gaa | gct | ttc | ttt | ||||||||||||
| ||||||||||||||||||||||||
10040 | 84% | 28 | C | A | S | T | S | G | A | A | T | N | E | K | L | F | F | 1-4 | ||||||
tgt | gcc | agc | act | tca | ggg | gcg | gca | act | aat | gaa | aaa | ctg | ttt | ttt | ||||||||||
| ||||||||||||||||||||||||
10069 | 91% | 6-5 | C | A | S | S | Y | Q | G | A | T | E | A | F | F | 1-1 | ||||||||
tgt | gcc | agc | agt | tat | cag | ggc | gcc | act | gaa | gct | ttc | ttt | ||||||||||||
| ||||||||||||||||||||||||
10032 | 99% | 6-2 | C | A | S | S | F | Q | G | Q | Q | P | Q | H | F | 1-5 | ||||||||
tgt | gcc | agc | agt | ttc | cag | ggg | caa | cag | ccc | cag | cat | ttt | ||||||||||||
| ||||||||||||||||||||||||
20 | 96% | 5-6 | C | A | S | S | L | F | G | T | G | G | N | T | E | A | F | F | 1-1 | |||||
tgt | gcc | agc | agc | ttg | ttc | ggg | aca | ggg | ggg | aac | act | gaa | gct | ttc | ttt |
Conserved glutamine (Q), serine (S) and threonine (T) within the D-segment are underlined. The dominant CDR3s were identical for DYS+ CD4+ TEM and TEMRA in all subjects.